DeepMind Spinout Isomorphic Labs Secures $5B Series C to Advance AI-Designed Drugs Toward Clinical Trials
Isomorphic Labs, the AI drug-discovery company spun out of DeepMind, raised $5 billion in a Series C co-led by Greenoaks and Sequoia, with Andreessen Horowitz and existing backers participating. The company builds on AlphaFold-derived simulation models, reports positive preclinical results in oncology and immunology, and will use the funds to expand its drug-design engine into more medicine types. The round follows Demis Hassabis stepping down as DeepMind head to focus on Isomorphic, with a reported target valuation of around $50 billion.
Skynet Chance (+0.01 pp): The funding goes to narrow, domain-specific scientific AI for drug design, which adds little to general autonomy or control risks. It does slightly expand powerful AI-driven chemistry and biology capabilities, which carry modest dual-use concerns.
Skynet Date (no change): Heavy investment in AI-for-science marginally speeds advanced capability development in sensitive domains. It does not meaningfully accelerate general-purpose systems that would drive loss-of-control timelines.
AGI Progress (+0.01 pp): Scaling AlphaFold-style scientific models shows AI tackling complex real-world scientific reasoning and design, a relevant if narrow step. The work is specialized rather than a general capability advance.
AGI Date (no change): A $5B raise and Hassabis's full-time focus pull major talent and capital into AI-for-science, modestly speeding AI-driven scientific discovery. Because it diverts some leadership attention away from general frontier models, the net effect on AGI timing is limited.
<< All AI news for November 17, 2026
[ Get the daily index digest on Telegram → ]Related AI News
- OpenAI Raises $11 Billion at $1.25 Trillion Valuation Amid Cooling AI Market Sentiment
- OpenAI Cuts Funding Round Target to $20 Billion Amid Tepid Investor Demand
- OpenAI Reportedly Nears $30B Raise at $1.25 Trillion Valuation Ahead of IPO
- OpenAI Reportedly Seeks $30B Pre-IPO Round at $1.4 Trillion Valuation, Delays IPO Citing Safety
- Vivodyne Bets Robotic Human-Tissue Labs Can Fix AI Drug Discovery's Data Gap